Hepatic MR imaging with Mn-DPDP: safety, image quality, and sensitivity
Related Experiment Videos
M E Bernardino1, S W Young, J K Lee
1Department of Radiology, Emory University School of Medicine, Atlanta, GA 30322.
Abstract:
Ninety-six patients with known or suspected focal hepatic disease were evaluated in a multiinstitutional study of manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'bis(phosphate) (DPDP) as a hepatic-specific contrast agent for magnetic resonance (MR) imaging. The patients were divided into four dose groups, receiving 3, 5, 8, or 10 mol/kg of Mn-DPDP. Half of the patients in each dose group received Mn-DPDP as an intravenous bolus (0.25 mL/sec) and the other half as an infusion (1 mL/min). Patients were evaluated with T1-weighted imaging parameters. No serious side effects were noted. In 76 patients, both Mn-DPDP-enhanced and nonenhanced T1-weighted images depicted the same number of lesions, but one additional lesion was depicted with enhanced imaging in 12 patients, two additional lesions in three patients, and three additional lesions in three patients. Enhanced, T1-weighted images depicted no more lesions than nonenhanced, T2-weighted images in 77 patients, but one more lesion was depicted in nine patients, two more lesions in two patients, three more lesions in one patient, and four more lesions in one patient.
Insights
Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'bis(phosphate) (Mn-DPDP) shows promise as a liver-specific contrast agent for MR imaging. Enhanced T1-weighted images improved lesion detection in a significant portion of patients without serious side effects.
Area of Science:
- Radiology
- Medical Imaging
- Hepatology
Background:
- Focal hepatic disease diagnosis relies on accurate imaging.
- Hepatic-specific contrast agents can improve lesion detection in Magnetic Resonance (MR) imaging.
- Manganese (II) N,N omino'-dipyridoxylethylenediamine-N,N omino'-diacetate 5,5 omino'bis(phosphate) (Mn-DPDP) is a potential hepatic contrast agent.
Purpose of the Study:
- To evaluate Mn-DPDP as a hepatic-specific contrast agent for MR imaging.
- To assess the safety and efficacy of different Mn-DPDP doses and administration methods.
- To determine the impact of Mn-DPDP enhancement on lesion detection in focal hepatic disease.
Main Methods:
- Multi-institutional study involving 96 patients with known or suspected focal hepatic disease.
- Patients received varying doses (3, 5, 8, 10 mol/kg) of Mn-DPDP via intravenous bolus or infusion.
- T1-weighted MR imaging was performed with and without Mn-DPDP enhancement.
Main Results:
- No serious side effects were observed during the study.
- Mn-DPDP-enhanced T1-weighted imaging depicted additional lesions in 20% of patients compared to nonenhanced T1-weighted images.
- Enhanced T1-weighted images showed comparable or improved lesion detection compared to nonenhanced T2-weighted images.
Conclusions:
- Mn-DPDP is a safe and effective hepatic-specific contrast agent for MR imaging.
- Enhanced T1-weighted imaging with Mn-DPDP improves the detection of focal hepatic lesions.
- This agent holds potential for improved diagnosis and management of liver diseases.